Talquetamab: New drug may offer hope for those with hard-to-treat blood cancer
Multiple myeloma is the second-most-common blood cancer, but is currently regarded as not curable. In multiple myeloma, plasma cells, a part of the immune system, multiply out of control and prevent the formation of other blood cells. Current treatments include chemotherapy and stem cell transplants. In phase 2 trials of a new treatment, talquetamab, around 73% of participants showed a […]
Continue reading »